Observational Study for Patients With Dilated Cardiomyopathy
1 other identifier
observational
500
1 country
1
Brief Summary
Observational study on patients with dilated cardiomyopathy aims to investigate the correlation between cardiac fibrosis, as indicated by cardiac magnetic resonance, and the prognosis of patients with dilated cardiomyopathy, and further to explore biomarkers for cardiac fibrosis and adverse prognosis of dilated cardiomyopathy. Therefore, endpoints indluding all-cause mortality, cardiovascular death, ventricular arrythmia, non-fatal stroke, non-fatal myocardial infarction, sudden death, successful cardiopulmonary resuscitation will be evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2019
CompletedFirst Submitted
Initial submission to the registry
April 6, 2021
CompletedFirst Posted
Study publicly available on registry
April 8, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2025
CompletedApril 8, 2021
April 1, 2021
6 years
April 6, 2021
April 6, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
All-cause death
All-cause mortality refers to death from any causes.
5 YEARS.
Secondary Outcomes (8)
Cardiovascular death
5 YEARS.
Ventricular tachycardia and fibrillation and flutter
5 YEARS.
nonfatal stroke
5 YEARS.
nonfatal myocardial infarction
5 YEARS.
sudden death
5 YEARS.
- +3 more secondary outcomes
Study Arms (1)
Subjects with dilated cardiomyopathy
Subjects diagnosed with dilated cardiomyopathy by medical history, physical examination and echocardiography.
Interventions
As an observational study, no intervention nor exposure is interested.
Eligibility Criteria
Patients diagnosed with dilated cardiomyopathy by medical history, physical examination and echocardiography.
You may not qualify if:
- Cardiac enlargement caused by other factors such as myocardial ischemia, myocarditis, diabetic cardiomyopathy, valvular heart disease, congenital heart disease, Patients who had underwent heart transplatation. Individuals not suitable for the present study due to maligant tumor or severe trauma.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Guangdong cardiovascular institute
Guangzhou, Guangdong, 510080, China
Biospecimen
plasma, serum, whole blood, and white blood cells
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Cheng Huang, PhD
Guangdong Cardiovascular institute, Dongchuan Road,96#, Guangzhou City, Guangdong Province
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PROFESSOR
Study Record Dates
First Submitted
April 6, 2021
First Posted
April 8, 2021
Study Start
January 1, 2019
Primary Completion
January 1, 2025
Study Completion
January 1, 2025
Last Updated
April 8, 2021
Record last verified: 2021-04
Data Sharing
- IPD Sharing
- Will not share
A part of participants do not want their privacy to be shared by other reserchers.